Changing of API registration in China NMPA- What you need to know
On January 17, 2020 The Center of Drug Evaluation has published a Notice on improving the relevant functions of the API registration system,
Indonesia: A look at Indonesia’s Halal Product Law
Indonesia’s Halal Product Law Criteria and a review of the halal global market and foreign company halal accreditation process
Antimicrobial Drugs Clinical Study Regulations Harmonization
The FDA, EMA and PMDA aim at bringing harmonization in regulations related to clinical studies conducted for novel antimicrobial drugs (antibacterial and antifungal) across USA, Europe and Japan.
NMPA’s UDI Requirements in China for Medical Device Manufacturers
NMPA had issued rules for Medical Device identification under Order 66, released in October 2019, which states that medical devices marketed in China shall comply with UDI regulations and implementation plan.
China’s CMDE announces new regulations on the supervision and adminstration of customized medical devices for clinical trials.
China’s CMDE Announces new Regulations on the Supervision AND Administration of Customized Medical Devices for Clinical Trials
Drug Master File (DMF) in China
The new system set up by the NMPA allows manufacturers to file the DMF directly, thereby reducing the approval time and respective cost involved.
China Expediting the Review and Approval of Drugs to Treat Life Threatening Diseases
Chinese health authority published a list with 48 orphan drugs that qualify for an expedite review process of their registration application. The 48 drugs are used for the treatment or prevention of rare and life-threatening diseases, and have alread…
New Program for the Review of Innovative Medical Devices in China
The Chinese National Medical Products Administration (NMPA) has published revised requirements for its innovative medical device review program that will take effect December 1, 2018. The new NMPA policy, Order 83 [2018] includes three major changes: Applications for Innovative Devices must be submitted to NMPA within five years of patent publications; Application review timeframes will […]
CFDA Announced Major Changes to Chinese Medical Device Regulations in favor of Foreign Manufacturers
China Food and Drug Administration (CFDA) proposed major changes to medical device regulatory requirements by amending Order No. 650. The timeframe for the implementation of such changes has not been announced by CFDA yet, but foreign medical manufacturers are welcoming the new changes as they will address the major issues they are facing while registering […]
Japan PMDA Raising Medical Device Registration Fees
[vc_row][vc_column][vc_column_text]On April 1st, 2018, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has raised the registration fees for most medical devices . PMDA fee increase is ranging from 8% to 15% across nine device categories as …
China New Policy Pushing Generics over Brands
On Tuesday April 3rd, 2018, the Chinese government published a new policy that promotes the usage of generics over brands in China. As an incentive, the qualified generics companies will be considered as high-tech enterprises, and therefore will be imposed a corporate tax rate of 15% instead of 25%. Additionally, generic that pass the quality […]
Japan cutting prices of new drugs and off-patent drugs
The Ministry of Health, Labor and Welfare is proposing a considerable cut down in the pricing of both off-patent drugs and expensive innovative treatments, and also set up an annual review of the drug prices.